Evidence Level
D-Ribose is a supplement studied for its potential benefits in various health conditions. Its mechanism of action revolves around ATP resynthesis, particularly in tissues where ATP depletion occurs. However, clinical evidence supporting its use in athletic performance remains limited, as healthy athletes typically do not experience significant ATP depletion during normal training.
In the context of heart failure, several studies have demonstrated promising results. Omran et al. (2003) found that D-ribose improved diastolic function and quality of life in patients with congestive heart failure. Similarly, Pliml et al. (1992) reported beneficial effects on exercise-induced ischemia in patients with stable coronary artery disease. More recent studies have further corroborated these findings. For instance, Petrov et al. (2025) conducted a randomized trial involving 68 heart failure patients and found that multi-ingredient supplementation, including D-ribose, combined with high-intensity training significantly improved exercise capacity, quality of life, and cardiac function compared to ubiquinol-based supplementation.
Additionally, Yu et al. (2024) reviewed 19 randomized clinical trials and concluded that individualized nutrition support, which may include D-ribose, reduces mortality and major cardiovascular events in chronic heart failure patients at high nutritional risk. Pierce et al. (2022) also reported significant improvements in symptoms and cardiac performance in a phase 2 trial of HFpEF patients treated with ubiquinol and/or D-ribose.
Despite these findings, the use of D-ribose in healthy individuals or athletes remains controversial. A systematic review by Song et al. (2022) found that higher doses of D-ribose caused significant cognitive impairment in rodents, potentially due to increased advanced glycation end products (AGEs). This highlights the need for caution and further research into its safety and efficacy across different populations.
In summary, while D-ribose shows promise in improving cardiac function and quality of life in heart failure patients, its role in athletic performance remains underwhelming. Further studies are needed to fully understand its benefits and risks in various clinical settings.